N/A
Average UserN/A
Average AnalystVery Bullish
Stock Target AdvisorUSD 182.50
0.00 (0.00)%
USD 40.34B
3.00
N/A
N/A
Average UserN/A
Average AnalystVery Bullish
Stock Target AdvisorUSD 40.34B
USD 182.50
Based on the Alexion Pharmaceuticals Inc stock forecasts from 0 analysts, the average analyst target price for Alexion Pharmaceuticals Inc is not available over the next 12 months. Alexion Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Alexion Pharmaceuticals Inc is Very Bullish, which is based on 2 positive signals and 0 negative signals. At the last closing, Alexion Pharmaceuticals Inc’s stock price was USD 182.50. Alexion Pharmaceuticals Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generaliz...Read More
121 Seaport Boulevard, Boston, MA, United States, 02210
3,837
December
USD
USA
1.26
N/A
5.36
N/A
9,803,110
USD 165.77
8,553,633
USD 182.75
0.27%
4.44%
88.02%
N/A
Security | Capital Gain | Dividend Return | Total Return |
---|
N/A
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
|
Legal & General UCITS ETF.. | 3.37 % | 0.49 % | -0.11 (-0.95%) | USD0.04B |
|
L&G Pharma Breakthrough U.. | 3.37 % | 0.49 % | -0.10 (-0.93%) | USD0.04B |
|
L&G Pharma Breakthrough U.. | 3.37 % | 0.00 % | -0.06 (-0.54%) | N/A |
|
iShares IV Public Limited.. | 3.22 % | 0.35 % | +0.04 (+0.63%) | USD0.46B |
|
iShares Nasdaq US Biotech.. | 3.22 % | 0.35 % | -0.10 (-1.69%) | USD0.46B |
|
iShares Nasdaq US Biotech.. | 3.22 % | 0.00 % | -0.01 (-0.11%) | USD0.47B |
|
ProShares UltraShort Nasd.. | 3.02 % | 0.95 % | +0.06 (+0.33%) | USD4.60M |
|
ProShares UltraPro Short .. | 3.02 % | 0.95 % | 0.00 (0.00%) | USD2.51M |
|
Direxion Daily S&P Biotec.. | 0.00 % | 1.00 % | -0.37 (-2.68%) | USD0.16B |
|
ProShares UltraPro Nasdaq.. | 0.00 % | 0.95 % | 0.00 (0.00%) | USD0.02B |
Heading 1 | Heading 2 | Heading 3 | Heading 4 | Heading 5 |
---|---|---|---|---|
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
Data 1 | Data 2 | Data 3 | Data 4 | Data 5 |
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.